Evaluation of the occurrence of sexual dysfunction and general quality of life in female patients with psoriasis*

Patricia Shu Kurizky1,2, Gladys Aires Martins3, Jamille Nascimento Carneiro4, Ciro Martins Gomes5, Licia Maria Henrique da Mota6,7

DOI: http://dx.doi.org/10.1590/abd1806-4841.20183071

Abstract: BACKGROUND: Psoriasis has a significant impact on quality of life (QoL). Sexual life can also be affected, with sexual dysfunction being reported by 25-70% of patients.
OBJECTIVES: To determine the occurrence of sexual dysfunction and evaluate QoL in women with psoriasis.
METHODS: This case-control study included women aged 18-69 years. The validated Brazilian Portuguese versions of the Female Sexual Function Index (FSFI) and of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) were administered to all participants to assess sexual function and QoL, respectively. Patients with psoriasis underwent clinical evaluation for the presence of comorbidities, especially psoriatic arthritis and other rheumatic manifestations. Location of lesions and the extent of skin involvement were also assessed.
RESULTS: The sample consisted of 150 women, 75 with diagnosis of psoriasis and 75 healthy controls. Prevalence of sexual dysfunction was high in women with psoriasis (58.6% of the sample). Prevalence was statistically higher in women with psoriasis than in controls (P=0.014). The SF-36 domain scores were also lower in women with psoriasis, with role limitations due to physical health, limitations due to emotional problems, and mental health being the most affected domains.
STUDY LIMITATIONS: Sample size was calculated to evaluate the association between the occurrence of sexual dysfunction and psoriasis, but it did not include the determination of the possible causes of this dysfunction.
CONCLUSIONS: QoL and sexual function were altered in women with psoriasis and should be taken into consideration when assessing disease severity.
Keywords: Arthritis; Psoriatic; Psoriasis; Quality of life; Sexual dysfunction, physiological

INTRODUCTION
Psoriasis is a chronic systemic inflammatory disease that involves mainly the skin and joints, affecting 1-3% of the world population.1-3 In Brazil, there are still no studies on its incidence and prevalence, but it is estimated that 1% of the Brazilian population has psoriasis.4 Its impact on quality of life (QoL) has been studied since the 1970s, when Jobling observed that more than 80% of patients presented difficulties in establishing social relations, considered the most daunting aspect of their illness.5,6 Since then, interest has increased in the quality of life and psychosocial wellbeing of psoriasis patients. Many studies have shown that psoriasis triggers feelings

Received 21 August 2013.
Accepted 13 October 2017.
* Work conducted at Hospital Universitário de Brasília, Universidade de Brasília, Brasília (DF), Brazil.
Financial support: None.
Conflict of interest: None.

1 Dermatology Service, Hospital das Forças Armadas, Brasilia (DF), Brazil.
2 Dermatology Service, Hospital Universitário de Brasília, Universidade de Brasília, Brasilia (DF), Brazil.
3 Psoriasis Outpatient Clinic, Hospital Universitário de Brasília, Universidade de Brasília, Brasilia (DF), Brazil.
4 Rheumatology Service, Hospital de Base do Distrito Federal, Brasilia (DF), Brazil.
5 Course in Dermatology, Universidade de Brasília, Brasilia (DF), Brazil.
6 Initial Rheumatoid Arthritis Outpatient Clinic, Hospital Universitário de Brasília, Universidade de Brasília, Brasilia (DF), Brazil.
7 Graduate Studies Program in Medical Sciences, Universidade de Brasília, Brasilia (DF), Brazil.

MAILING ADDRESS:
Patricia Shu Kurizky
E-mail: patyshu79@gmail.com

©2018 by Anais Brasileiros de Dermatologia
of depression, shame, and anxiety, culminating in social isolation.2,7,11
Al-Mazeedi et al. reported that psoriasis inhibited new relations in 48.2% of patients, and two-thirds were concerned about the
relations and perceptions of others in relation to their condition.8

One of the key points in maintaining QoL, as defined by
the World Health Organization, is sexuality.12 Sexual dysfunction is
characterized by lack of adequate functioning of one of the phases
comprising the sexual cycle. In women, sexual dysfunction is
defined as disorders of desire, libido, or arousal, pain or discomfort,
and anorgasmia.13

Although sexual dysfunction is a common complaint, af-
flecting 30 to 70% of psoriasis patients, few studies have analyzed
the impact of psoriasis and psoriatic arthritis on quality of sexual
life, and none has addressed the Brazilian population.14,15 The aim
of this article was to assess the occurrence of sexual dysfunction in
psoriasis using a case-control study with Brazilian women.

METHODS

A case-control study was performed with a convenience
sample consisting of patients with a diagnosis of psoriasis (psoria-
sis group) treated at a specialized Dermatology Outpatient Service
at Hospital Universitário de Brasília (HUB) and healthy volunteers
(healthy control group), matched for age, recruited at the Dermatol-
yogy Outpatient Clinic of Hospital das Forças Armadas (HFA) from
July 2011 to October 2012. The control group consisted of women
that were accompanying patients at the outpatient clinic and pa-
tients returning for follow-up, previously treated and without clin-
ical complaints at the time of recruitment.

The study was approved by the Institutional Review Board
of Faculdade de Medicina, Universidade de Brasília (case review
010/2011).

Inclusion criteria for all the women were: age 18 to 69 years,
active sexual life, and clinical diagnosis of psoriasis, as determined
by the same physician, an experienced dermatologist, and or clinical-
pathology study. For the control group, an inclusion criterion was
the absence of diagnosis of psoriasis or psoriatic arthritis.

Exclusion criteria were: gynecological disorder potentially
affecting sexual function (including vaginitis, endometriosis, chron-
ic pelvic pain, malignant neoplasm, uterine cervical dystopia, vagi-
nism, and alterations of the pelvic anatomy); pregnancy; prior psy-
chiatric diagnosis or concurrent with psoriasis (depression, anxiety,
phobias, psychopathy); diagnosis of rheumatic diseases or others
that course with arthritis (rheumatoid arthritis, spondyloarthritis,
microcrystalline arthritis), which can cause confounding or doubt as
to the diagnosis of possible psoriatic arthritis; diagnosis of chronic,
extensive skin disorders such as dermatitis, pityriasis rubra pilaris,
bullous dermatoses, vitiligo, ichthyosis, acne grade two or greater,
and genital mucocutaneous diseases.

After signing informed consent, all participants underwent
a clinical assessment that recorded epidemiological data like age,
centity, schooling, and marital status, besides clinical data such as
past medical history and use of medications. In psoriasis patients,
the location of the lesions was also verified (genital involvement,
unual involvement, and involvement of exposed skin areas, the
latter defined for purposes of this study as lesions located on the
face, scalp, and hands) and extent of the disease, assessed by the
Psoriasis Area Severity Index (PASI).16 Next, patients were submit-
ted to the version validated in Brazilian Portuguese of the Female
Sexual Function Index (FSFI) and the Medical Outcome Study 36-
item Short Form Health Survey (SF-36).17,18 Finally, women with
any complaints pertaining to the joints were examined by an ex-
perienced rheumatologist (always the same physician), in order
to assess the presence of psoriatic arthritis, based on the CASPAR
classification criteria.19

The FSFI is a questionnaire that aims to assess female sexual
response through analysis of the five domains of sexual function:
desire and subjective arousal, lubrication, orgasm, satisfaction, and
pain/discomfort. Individual scores are obtained by the sum of the
items that include each domain (simple score), which are multiplied
by this domain’s factor, furnishing the weighted score. The final
score (minimum two, maximum 36) is obtained by the sum of the
weighted scores in each domain. A total score of 26 or less indicates
greater risk of sexual dysfunction.20

SF-36 is a 36-item questionnaire that assesses eight domains
of QoL: physical functioning, role physical, bodily pain, general
health, vitality, social functioning, role emotional, and mental
health. The score for each domain varies from zero to 100, where
zero is the worst health status and 100 is the best.21

Statistical analysis

The sample calculation was done initially in a pilot study with
67 women (47 with psoriasis and 20 controls), evaluating the
variables obtained with the desire indices from the FSFI by means
of the Wilcoxon test with 95% confidence interval, leading to 88%
test power for a sample of 150 women with a difference of one point.

Analyses of the association between variables used the R
software, version 2.15.1 (R Foundation for Statistical Computing,
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.
org/). The Kolmogorov-Smirnov test for normality was used to veri-
fy whether the sample’s data showed normal distribution. The distri-
bution was considered normal if p>0.05. Analysis of categorical vari-
ables was based on the chi-square test of independence. When data
for the variables were less than five, the p-value from the Monte Carlo
simulated Fisher’s exact test was used, as proposed by Hope, 1968.22
The association between quantitative variables was investigated in
two ways: a) by means of categorization of the variables, followed by
analysis using the chi-square test or Monte Carlo simulated p-value;
b) by calculation of Pearson’s correlation coefficient, when the vari-
ables showed two-tailed normal distribution, or Spearman’s rank
correlation coefficient for cases that did not show this distribution.
Finally, analysis of covariance was applied to assess quantitative tar-
get variables from FSFI and SF-36, adjusted for covariates that could
influence the study’s results. The categories of some covariates were
grouped so as to increase the model’s explanatory capacity and good-
ness of fit. Statistical significance was set at 5%.

RESULTS

The study’s sample size was 150 women, of whom 75 in
the control group and 75 in the psoriasis group, both with mean
age 45 years and standard deviation approximately 12 years. All

An Bras Dermatol. 2018;93(6):801-6.
the patients diagnosed with psoriasis were caucasian or of mixed races. The control group included a few black and Asian-descendent women, but the vast majority were caucasian or of mixed races (92%). In both groups, the majority of women were married, but the proportion of unmarried women and those not living with a partner (i.e., single, divorced, or widows) was higher (42.66%) in the psoriasis group. As for education, the control group included predominantly women with more than seven years of schooling, while the psoriasis group included mostly those with one to seven years of schooling. Only two illiterate women participated in the study, both with psoriasis.

As for clinical status of psoriasis, most of the patients presented psoriasis vulgaris, and for disease site, 20% presented genital involvement, 33% ungual involvement, and 30% with lesions on exposed areas. PASI scores varied from 0 to 21.4, with a median score of 3.6 (interquartile range, 6.3). Comorbidities were present in 45% of the control group and 72% of the psoriasis group. Chi-square test showed a statistically significant association between presence of comorbidities and psoriasis (p=0.023). Rheumatological assessment was performed in 38 of the 75 patients diagnosed with psoriasis, of whom 16 had a diagnosis of fibromyalgia, ten of psoriatic arthritis, and two of osteoarthritis; 31 patients denied any kind of rheumatic manifestation. Tables 1 and 2, respectively, show the psoriasis group’s clinical characteristics and analysis of comorbidities.

**Table 1: Clinical characteristics of psoriasis group**

| Extent of psoriasis (PASI) | Psoriasis group |
|----------------------------|----------------|
| 0-21.4 (Median 3.6)       | 69 (92%)       |

| Clinical type of psoriasis |
|----------------------------|
| Psoriasis vulgaris          | 69 (92%)       |
| Palmoplantar psoriasis     | 4 (5.3%)       |
| Guttate psoriasis          | 1 (1.3%)       |
| Erythrodermic psoriasis    | 1 (1.3%)       |

| Ungual involvement         |
|----------------------------|
| Present                    | 25 (33.3%)     |
| Absent                     | 50 (66.6%)     |

| Genital involvement        |
|----------------------------|
| Present                    | 15 (20%)       |
| Absent                     | 55 (73.3%)     |
| Missing data               | 5 (6.7%)       |

| Involvement of exposed areas* |
|------------------------------|
| Present                      | 23 (30.7%)     |
| Absent                       | 48 (64%)       |
| Missing data                 | 4 (5.3%)       |

| Associated rheumatologic diagnosis |
|------------------------------------|
| Fibromyalgia                       | 16 (21.3%)     |
| Psoriatic arthritis                | 10 (13.3%)     |
| Osteoarthritis                     | 2 (2.6%)       |
| Others                             | 10 (13.3%)     |
| Absence of rheumatologic alterations | 31 (41.3%) |
| Missing data                       | 6 (8%)         |

* Lesions present on face, scalp, and hands

**Quality of life indices (SF-36)**

Analysis of covariance revealed significantly worse indices in the psoriasis group, adjusted for age, skin color, schooling, and marital status in the domains role physical (p=0.002), role emotional (p=0.029), and mental health (p=0.021) (Table 3).

**Table 2: Assessment of comorbidities in the psoriasis group and control group (chi-square test)**

| Presence of comorbidity | Psoriasis group | Control group | p-value |
|-------------------------|-----------------|---------------|---------|
| SAH                     | 18 (24%)        | 14 (18.6%)    | 0.43    |
| DM                      | 14 (18.6%)      | 8 (10.7%)     | 0.17    |
| Dyslipidemia            | 16 (21.3%)      | 7 (9.3%)      | 0.042   |
| Absence of comorbidity  | 19 (25.3%)      | 28 (37.3%)    | 0.47    |
| Missing data            | 2 (2.6%)        | 13 (17.3%)    |         |

**Table 3: Comparison of quality of life (SF-36) between the groups with and without psoriasis, adjusted by age, ethnicity, schooling, and marital status (analysis of covariance)**

| PHYSICAL FUNCTIONING - SF36 | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 80.3 | 20.0               | 0.641    |
| Patient                     | 78.7 | 24.5               |          |

| ROLE PHYSICAL - SF36        | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 72.3 | 39.1               | 0.002    |
| Patient                     | 45.0 | 47.2               |          |

| BODILY PAIN - SF36          | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 63.8 | 24.4               | 0.503    |
| Patient                     | 62.3 | 29.6               |          |

| GENERAL HEALTH - SF36       | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 70.3 | 19.9               | 0.169    |
| Patient                     | 62.8 | 27.3               |          |

| VITALITY - SF36             | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 61.3 | 19.0               | 0.081    |
| Patient                     | 55.7 | 28.5               |          |

| SOCIAL FUNCTIONING - SF36   | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 75.3 | 21.0               | 0.191    |
| Patient                     | 69.2 | 32.3               |          |

| ROLE EMOTIONAL - SF36       | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 67.6 | 39.0               | 0.029    |
| Patient                     | 47.6 | 47.8               |          |

| MENTAL HEALTH - SF36        | Mean | Standard deviation | p-value* |
|-----------------------------|------|--------------------|----------|
| Control                     | 69.3 | 16.5               | 0.021    |
| Patient                     | 59.6 | 28.0               |          |

SAH – systemic arterial hypertension; DM – diabetes mellitus

* Adjusted for age, schooling, marital status, and ethnicity
* significance: p-value < 0.05
Sexual dysfunction (FSFI)

Forty-four patients (58.6%) and 29 controls (38.6%) showed FSFI score less than or equal to 26, with a chi-square test with p-value 0.014, demonstrating higher occurrence of sexual dysfunction in psoriasis patients, with 95% confidence.

Analysis of the association between diagnosis of psoriasis and each of the domains (desire, arousal, lubrication, orgasm, satisfaction, and pain), separately, adjusted for age, race, schooling, and marital status was done by analysis of covariance. Table 4 shows that the statistical difference was maintained, evidencing that the score in the control group was higher than in the group of psoriasis patients for all the domains.

Sexual dysfunction showed a statistically significant association with the extent of skin involvement (p-value=0.04). However, this association was not observed when analyzing the different lesion sites by means of the chi-square test: genital involvement was present in 25% of the women without sexual dysfunction and in 19% of those with sexual dysfunction, p-value=0.55; ungual involvement in 32.3% of women without sexual dysfunction and in 34.1% of women with sexual dysfunction, p-value=0.868; and involvement of exposed skin areas in 39.3% of women without dysfunction and in 27.9% of women with sexual dysfunction (p-value=0.32).

The association between sexual dysfunction and comorbidities was analyzed by the chi-square test in the psoriasis group (66.7% of women without dysfunction and 79% of women with sexual dysfunction presented comorbidity) and did not show a statistically significant association (p=0.273). As for diagnosis of rheumatic disease, assessed in 69 of the 75 patients included in the study, the chi-square test showed a p-value of 0.91 (53.6% of women without dysfunction and 56.1% of women with sexual dysfunction presented some type of rheumatic disease). Although no statistically significant association was observed between presence of rheumatic disease concurrent with psoriasis and the occurrence of sexual dysfunction, the total FSFI score in women with fibromyalgia was lower (mean 15.4) than in the remaining of the psoriasis group (mean 19.6).

**DISCUSSION**

The current study confirmed the impact of psoriasis on QoL, demonstrating that the domains assessed with the SF-36 questionnaire, especially role physical, vitality, role emotional, and mental health are worse in women with psoriasis when compared to healthy controls. These data are consistent with previous studies in the literature.\textsuperscript{22} Al-Mazeedi et al. observed the effect of psoriasis on physical activities and reported that open-air activities and sun-bathing were affected in half of the cases, and light exercises, such as walking, were jeopardized in 77.3% of patients.\textsuperscript{8} The functional limitation is due mainly to pruritis, irritation, and pain. Palmoplantar psoriasis and psoriatic arthritis add a negative effect to QoL, since they directly affect activities of daily living.\textsuperscript{4}

According to Chiozza, psoriasis patients, more than patients with other dermatologic diagnoses, fear social isolation and rejection and harbor fantasies of abandonment.\textsuperscript{24} Approximately 26% of psoriasis patients report family tensions resulting from the disease, 50% limit their participation in sports activities, and 40% experience some difficulty in the workplace.\textsuperscript{25}

A recent systematic literature review aimed to assess the prevalence of sexual dysfunction in patients with psoriasis and psoriatic arthritis, analyzing such factors as depression and extent of the disease in this relationship.\textsuperscript{26} The review analyzed 4,039 psoriasis patients, of whom 2,567 were men (63.55%) and 1,472 were women (36.45%), with age ranging from 23 to 62 years. In all the studies, patients were assessed as to sexual function based on self-administered questionnaires, and some studies also evaluated psychological aspects and QoL. Although the study populations and questionnaires varied, sexual dysfunction was prevalent in all the studies (ranging from 22.6% to 71.3%).\textsuperscript{26}

Later publications also addressed the subject, with prevalence of sexual dysfunction ranging from 50% to 65%.\textsuperscript{25, 27-31} Prevalence of sexual dysfunction in our patients was high (58.6%), statistically higher than in the control group (38.6%). This difference was maintained in the analysis of the association between diagnosis of psoriasis and each of the domains separately (desire, arousal, lubrication, orgasm, satisfaction, and pain), adjusted by age, race, schooling, and marital status, showing that sexual dysfunction is more frequent in the group of psoriasis patients in all the domains.

Analysis of the psoriasis group showed that patients reporting sexual dysfunction also presented more extensive skin lesions. This same relationship had been observed by Sampogna et al. in 2007\textsuperscript{27}, later confirmed by Guenther et al. in 2011,\textsuperscript{25} although it is not a consensus.\textsuperscript{8, 12, 25, 30, 34-37}

Various factors can impact the quality of sexual life in psoriasis patients, including side effects of medications, increased prevalence of comorbidities,\textsuperscript{26} lesion site, and symptoms of the skin condition itself, such as pruritis, psychological alterations, and the partner’s concerns.\textsuperscript{33}

Comorbidities were prevalent in the psoriasis group, as reported in previous studies.\textsuperscript{29, 34} Previous studies have reported a relationship between chronic diseases, especially rheumatic comorbid-

| Table 4: Comparison of FSFI between the groups with and without psoriasis, adjusted for age, ethnicity, schooling, and marital status (analysis of covariance) |
| --- |
| **Mean** | **Standard deviation** | **p-value** |
| **DESIRE** |  |  |
| Control | 3.6 | 1.2 | 0.019 |
| Patient | 3.2 | 1.3 |  |
| **AROUSAL** |  |  |
| Control | 3.9 | 1.8 | 0.001 |
| Patient | 2.6 | 2.2 |  |
| **LUBRICATION** |  |  |
| Control | 4.3 | 1.9 | 0.014 |
| Patient | 3.1 | 2.6 |  |
| **ORGASM** |  |  |
| Control | 4.2 | 1.8 | 0.017 |
| Patient | 3.1 | 2.7 |  |
| **SATISFACTION** |  |  |
| Control | 4.6 | 2.0 | 0.001 |
| Patient | 3.1 | 2.6 |  |
| **PAIN** |  |  |
| Control | 4.5 | 2.0 | 0.012 |
| Patient | 3.4 | 2.7 |  |

*p Results adjusted for age, race, schooling, and marital status
* significance: p-value ≤0.05
ities, and sexual dysfunction. However, this relationship was not significant, although patients with fibromyalgia presented lower FSFI scores, which is consistent with the high prevalence of sexual dysfunction described in patients with chronic pain. The absence of statistically significant results is probably due to the small numbers in each comorbidity, not allowing an adequate analysis of each condition.

The location of lesions also failed to show a significant association with sexual dysfunction, consistent with the study by Van Dorssen et al., although differing from results reported by other authors, who pointed to genital involvement as an important factor in quality of sexual life. A possible explanation could be that the presence of lesion has less influence than local symptoms on quality of sexual life in these patients. Zamirnka et al. assessed 93 women for vulvar pruritis or burning sensation (mons pubis, labia majora and minora, and clitoris). They found that 44.1% of women presented vulvar discomfort, 19.4%, pruritis, 10.8% burning sensation, and 14% both. However, only 22 women (23.7%) presented psoriatic lesions on the vulva, and 47.3% had a prior history of genital involvement. The authors showed a significant correlation between vulvar discomfort and genital involvement of psoriasis.

Note that prevalence of sexual dysfunction in the control group (38.6%) is slightly higher than the values found in other studies with healthy Brazilian women, where prevalence varied from 30% to 35.7%. This could be explained by the different epidemiological profiles of the study groups and the fact that women with chronic diseases, except for arthritis, or chronic drug use were not excluded.

Some limitations to the current study need to be addressed. First, although previous diagnoses of psychiatric disorders such as depression and anxiety were an exclusion factor, no specific psychiatric tests were applied.

Second, corroborating the literature, this group of patients with psoriasis also showed a high comorbidity rate (64%), including diabetes mellitus and hypertension, chronic conditions that are known to be associated with increased sexual dysfunction. Although prior sample calculation was performed to determine the number needed to assess the association between psoriasis and sexual dysfunction, the calculation did not cover the determination of the possible causes of such dysfunction. Thus, to determine the real influence of factors like emotional alterations and comorbidities, especially rheumatic diseases, a larger sample would probably be necessary. In addition, the complete exclusion of women with arthritis from the control group was intended to avoid the possibility of rare cases of psoriatic arthritis preceding cutaneous manifestation from being included erroneously in this group. However, this made the sample intentional, which can also be considered a bias.

CONCLUSION

Despite its limitations, our study was the first of its kind in female Brazilian patients, and the results proved important to confirm the impact of psoriasis on QoL, to identify the domains most affected, and to elucidate the relationship between this disease and alterations in sexual function. The high prevalence of sexual dysfunction in our patients highlights the need for a more comprehensive approach to the health of women with psoriasis, beyond assessment of their skin condition and the extent of the disease, including other QoL issues and specifically sexual function.

REFERENCES

1. Langham S, Langham J, Goertz HP, Ratcliffe M. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical view. BMC Med Res Methodol. 2011;11:32.
2. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3-11.
3. Carneiro JN. Artrite psoriásica em pacientes com psoríase: avaliação de características clínicas e epidemiológicas em um grupo de 133 pacientes brasileiros [thesis]. Brasília: Universidade de Brasília; 2011.
4. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2012. Guias de avaliação e tratamento Sociedade Brasileira de Dermatologia. 2. ed. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2012.
5. Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012;92:67-72.
6. Jobling R. Psoriasis - a preliminary questionnaire study of sufferers' subjective experience. Clin Exp Dermatol. 1976;1:233-6.
7. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:238-44.
8. Al-Mazeedi K, El-Shazy M, Al-Ajmi HS. Impact of psoriasis on quality of life in Kuwait. Int J Dermatol. 2006;45:418-24.
9. Martins GA, Al, Mugnaini AL. Validation of life quality questionnaires for psoriasis patients. An Bras Dermatol. 2004;79:521-35.
10. Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011 Jul;50:783-92.
11. Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of Psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life. Ann Dermatol. 2010;22:389-96.
12. World Health Organization. Division of Mental Health and Prevention of Substance Abuse. WHOQoL: measuring quality of life. Geneva: World Health Organization; 1997.
13. Ermertcan AT. Sexual dysfunction in dermatological diseases. J Eur Acad Dermatol Venereol. 2009;23:999-1007.
14. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997;36:259-62.
15. Ruiz-Villarverde R, Sánchez-Cano D, Rodríguez JR, Gutierrez CV. Pilot study of sexual dysfunction in patients with psoriasis: influence of biologic therapy. Indian J Dermatol. 2011;56:694-9.

16. Finlay AY GS. Error in the original description of the Psoriasis Area and Severity Index. Br J Dermatol. 1998;139:54.

17. Pacacanella Rde C, Martinez EZ, Vieira EM. Construct validity of a Portuguese version of the Female Sexual Function Index. Cad Saude Publica. 2009;25:2323-44.

18. Ciconelli RM, Ferraz MB, Santos W, Meinião C, Sanches RR, Melo F. A simplification of Monte Carlo significance test procedure. J Roy Statist B. 1975;26:381-9.

19. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2669-73.

20. Rosén R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191-208.

21. Ruiz-Villarverde R, Sánchez-Cano D, Rodríguez JR, Gutierrez CV. Pilot study of sexual dysfunction in patients with psoriasis: influence of biologic therapy. Indian J Dermatol. 2011;56:694-9.

22. Torres RA, Silva SA, Magalhães RF, Marcilio AM, Velho PE. Comparison of quality of life questionnaires and their correlation with the clinical course of patients with psoriasis. An Bras Dermatol. 2011;86:45-9.

23. Tejada Córs S, Mendoza-Sassi RA, Almeida HL Jr, Figueiredo PN, Tejada VF. Impact on the quality of life in dermatological patients in southern Brazil. An Bras Dermatol. 2011;86:1113-21.

24. Silva KS. Psoriasis and its relation with psychological, stress and events of life. Est Psicol. 2007;24:257-66.

25. Russo RA, Icher R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45:155-9.

26. Kurizky PS, Mota LMH. Distribution pattern of psoriasis, anxiety and depression in the Brazilian public: a prospective case series study. J Sex Med. 2013;10:1212-8.

27. Molina-Leiva A, Almodovar-Real A, Ruiz-Carrascos JC, Naranjo-Sintes R, Serrano-Ortega S, Jimenez-Moleon JL. Distribution pattern of psoriasis affects sexual function in moderate to severe psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol. 2011;25:851-7.

28. Molina-Leiva A, Almodovar-Real A, Ruiz-Carrascos JC, Naranjo-Sintes R, Jimenez-Moleon JL. Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis. An Bras Dermatol. 2015;90:338-45.

29. Serrano-Ortega S, Jimenez-Moleon JJ. Distribution pattern of psoriasis affects sexual function in patients with psoriasis: a longitudinal study. J Sex Med. 2011;8:1407-14.

30. Guenther L, Han C, Zhang Z, Wang M, Han Y, Wang L, et al. Erectile dysfunction in patients with plaque psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol. 2011;25:851-7.

31. Finlay AY GS. Error in the original description of the Psoriasis Area and Severity Index. Br J Dermatol. 1998;139:54.

32. Sampogna F, Gisondi P, Tabolli S, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences investigators. Impairment of sexual life in patients with psoriasis. Dermatology. 2007;214:144-50.

33. Guenthler L, Han C, Zhang Z, Wang M, Han Y, Bouricius M, et al. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol. 2011;25:851-7.

34. Rieder E, Tausk F. Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatments. Int J Dermatol. 2012;51:12-26.

35. Sampogna F, Tabolli S, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. The impact of changes in clinical severity on psychological morbidity in patients with psoriasis: a follow-up study. Br J Dermatol. 2007;157:508-13.

36. Keller MM, Wong JW, Nguyen TV, Lee ES, Bhutani T, Menter A, et al. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin. 2012;30:281-91, ix.

37. Maaty AS, Gomaa AH, Mohammed GF, Youssef EM, Eyada MM. Assessment of female sexual function in patients with psoriasis. J Sex Med. 2013:10:1545-8.

38. Goulding JM, Price CL, Defly CF, Hulangamuwa CS, Bader E, Ahmed I. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br J Dermatol. 2011;164:103-9.

39. Li K. Armstrong AW. A review of health outcomes in patients with psoriasis. Dermatol Clin. 2012;30:61-72, viii.

40. Lignan ED, Estève E. Psoriasis: une maladie systémique. Presse Med. 2012;41:338-48.

41. Leaumann RO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-44.

42. West SL, Vinkoor LC, Zolnoun D. A systematic review of the literature on female sexual dysfunction prevalence and predictors. Annu Rev Sex Res. 2004;15:40-72.

43. Türel Ermercanci A, Turel Ermercanci A, Deveci A, Dinc G, Gülder HB, Öztürkcan S. Sexual dysfunction in patients with psoriasis. J Dermatol. 2006;33:772-6.

44. van Dorsten IE, Boom BW, Hengeveld MW. Experience of sexuality in patients with psoriasis and constitutional eczema. Ned Tijdschr Geneeskd. 1992;136:2175-8.

45. Ryan C, Sadlier M, De Vol E, Patel M, Lloyd AA, Day A, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72:976-83.

46. Zamirns A, Reich A, Berry-Moreno J, Salomon J, Szepietowski JC, Vultur prurius and burning sensation in women with psoriasis. Acta Derm Venereol. 2008;88:132-5.

47. Abdo CHN, Moreira Jr ED, Fittipaldi JAS. Perfil sexual da população brasileira: resultado do estudo de comportamento sexual (EDOS) do brasileiro. Rev Bras Med. 2002;59:250-7.

48. Valadases AL, Pinho-Neto AM, Osnis MA, Sousa MH, Costa-Paiva L, Conde DM. Prevalence of sexual dysfunction and its associated factors in women aged 40-65 years with 11 years or more of formal education: a population-based household survey. Clinics (Sao Paulo). 2008;63:775-82.

How to cite this article: Kurizky PS, Martins GA, Carneiro JN, Gomes CM, Mota LMH. Evaluation of the occurrence of sexual dysfunction and general quality of life in female patients with psoriasis. An Bras Dermatol. 2018;93(6):801-6.